Esteve

Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 9, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, OPEX, ACOR, SG, Therapy, GAAP, Esteve, EBITDA, Government, Alkermes, Biotie Therapies, R, Acorda Therapeutics, Catalent, Cryptocurrency, Pharmaceutical industry, Video game, Reinsurance, Clothing, Music, Bookkeeping, Biogen, Açorda, 4-Aminopyridine, Nepicastat

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022.
  • “Acorda’s operating and financial performance improved throughout the year, meeting our financial guidance for 2022 AMPYRA net revenue, INBRIJA U.S. net revenue, cash, and adjusted OPEX.
  • For the quarter ended December 31, 2022, the Company reported AMPYRA net revenue of $18.8 million, a 16.6% decrease compared to the same quarter in 2021.
  • Additionally, for the quarter ended December 31, 2022, the Company reported FAMPYRA royalty revenues of $2.7 million, a 25.1% decrease compared to the same quarter in 2021.

ESTEVE Launches INBRIJA® in Spain

Retrieved on: 
Tuesday, March 7, 2023
Pharmaceutical, Health, Neurology, OFF, Equality, Disability-adjusted life year, Therapy, SEN, ACOR, News, Ministry, Central nervous system, Patient, Social services, DSM-IV codes, Federation, White paper, Parkinson's disease, Peaceful transition of power, Acorda Therapeutics, L-DOPA, Pharmaceutical industry, EU, Esteve, S.A

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Esteve Pharmaceuticals, S.A. has launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Esteve Pharmaceuticals, S.A. has launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain.
  • (1)
    As previously announced, under the terms of the supply agreement with Esteve, Acorda will receive a significant double-digit percent of the selling price of INBRIJA in Spain in exchange for supply of the product.
  • (2)
    “Today’s announcement is great news for people in Spain who are living with Parkinson’s and suffer from OFF periods.
  • Esteve is a leader in commercializing central nervous system therapeutics in Spain.

Esteve Launches INBRIJA® in Germany

Retrieved on: 
Thursday, June 16, 2022
Health, Neurology, Other Health, Physical Therapy, General Health, Pharmaceutical, Population, Intellectual property, Security (finance), Patent, COVID-19, OFF, Technology, Gesellschaft mit beschränkter Haftung, Neurodegeneration, Lists of diseases, U.S. Securities and Exchange Commission, Man, Forward-looking statement, Research, Açorda, Nerius, Acorda Therapeutics, Disease, Consultant, Phenelzine, Travel, ACOR, L-DOPA, Failure, Tablet, Acta Neurologica Scandinavica, Workforce, Nasdaq, Parkinson's disease, Adult, Incidence, Patient, Tranylcypromine, Inhalation, 4-Aminopyridine, Esteve, Therapy, Woman, Prevalence, Goal, Risk, Judgement, Pharmaceutical industry, EU

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany.
  • We are excited that INBRIJA is now available to the people with Parkinsons in Germany who may benefit from a new treatment to address their OFF periods, said Kerry Clem, Chief Commercial Officer of Acorda Therapeutics.
  • Esteve has a significant presence in Europe and an excellent track record of successfully commercializing neurological products there.
  • (2)
    Acorda had also previously announced an agreement with Esteve to commercialize INBRIJA in Spain with a commercial launch in early 2023 and an agreement with Biopas Laboratories to commercialize INBRIJA in Latin America.

Acorda Therapeutics Reports First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 11, 2022
Health, General Health, ACOR, Risk, Company, Consultant, R, Research, Cyprus Securities and Exchange Commission, Nasdaq, Esteve, Patient, Goal, Mission statement, Insurance, Phenelzine, Judgement, Therapy, Investor relations, Investor, COVID-19, Failure, OFF, Tablet, Workforce, Patent, Intellectual property, Omicron, Forward-looking statement, Budget, Technology, Inhalation, Travel, SG, Tranylcypromine, Q&A, GAAP, Security (finance), Biotie Therapies, Acorda Therapeutics, Lists of diseases, Mobile phone, Pharmaceutical industry, Video game, Bank, Webcast, 4-Aminopyridine, Açorda, L-DOPA

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2022.
  • For the quarter ended March 31, 2022, the Company reported INBRIJA net revenue of $3.7 million, compared to $5.0 million for the same quarter in 2021.
  • Change in fair value of derivative liability for the quarter ended March 31, 2022 was negligible, compared to $0.2 million for the same quarter in 2021.
  • A reconciliation of the GAAP financial results to non-GAAP financial results is included with the attached financial statements.

Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain

Retrieved on: 
Thursday, July 22, 2021
Biotechnology, General Health, Pharmaceutical, Health, Acorda Therapeutics, Drugs, Esteve, Life sciences, L-DOPA, Industry economics)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A (ESTEVE) to commercialize INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A (ESTEVE) to commercialize INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain.
  • (1)
    Under the terms of the supply agreement, ACORDA will receive a significant double-digit percent of the selling price of INBRIJA in Spain in exchange for supply of the product.
  • ESTEVE will have the exclusive distribution rights to INBRIJA in the territory and ACORDA will supply the product to ESTEVE.
  • ESTEVE expects to launch INBRIJA in Spain in the fourth quarter of 2022.

Amerant Names Christine Esteve as Chief Marketing Officer

Retrieved on: 
Wednesday, June 30, 2021
Chief marketing officer, Esteve, Carnival Cruise Line

MIAMI, June 30, 2021 /PRNewswire/ -- Amerant Bancorp Inc. (NASDAQ: AMTB and AMTBB) ("Amerant") announced today that Christine Esteve, a local marketing veteran with nearly 30 years of experience, has been named Executive Vice President (EVP) and Chief Marketing Officer (CMO).

Key Points: 
  • MIAMI, June 30, 2021 /PRNewswire/ -- Amerant Bancorp Inc. (NASDAQ: AMTB and AMTBB) ("Amerant") announced today that Christine Esteve, a local marketing veteran with nearly 30 years of experience, has been named Executive Vice President (EVP) and Chief Marketing Officer (CMO).
  • "...Christine's extensive experience will play an integral part in helping elevate our brand," Jerry Plush, Amerant CEO
    Prior to joining Amerant, Esteve was the Vice President of Performance Marketing at Carnival Cruise Line.
  • In her 28 years at Carnival, Esteve led multiple teams and managed initiatives in brand management, advertising, media, customer marketing, eCommerce and more.
  • "I'm thrilled to be joining Amerant, especially during an exciting time in its growth and evolution," added Esteve.

ESTEVE and KOWA Pharmaceuticals America enter into an Exclusive License and Commercialization Agreement for rights to E-58425 for the potential management of acute pain(1-9) in the United States(8,9)

Retrieved on: 
Monday, May 3, 2021
Esteve, Battle of Pusan Perimeter, Battles of the Korean War, Battles, Military history of Korea

b'BARCELONA, Spain, May 3, 2021 /PRNewswire/ --Esteve Pharmaceuticals (ESTEVE), an international specialty pharmaceutical company devoted to the development and commercialization of innovative products, today announced an agreement with Kowa Pharmaceuticals America, Inc. (KPA) under which ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States.

Key Points: 
  • b'BARCELONA, Spain, May 3, 2021 /PRNewswire/ --Esteve Pharmaceuticals (ESTEVE), an international specialty pharmaceutical company devoted to the development and commercialization of innovative products, today announced an agreement with Kowa Pharmaceuticals America, Inc. (KPA) under which ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States.
  • A decision on its approval is expected this year.\nESTEVE will be the supplier of the product and will retain worldwide rights to this product, except in the United States and Canada.
  • If approved by FDA, patients and healthcare providers will have access to a new treatment option for acute pain management in adults.
  • "\nBen Stakely, CEO of KPA, said: "We are delighted to be working with an innovative company like ESTEVE to introduce E-58425 to the United States market.

ESTEVE and KOWA Pharmaceuticals America enter into an Exclusive License and Commercialization Agreement for rights to E-58425 for the potential management of acute pain(1-9) in the United States(8,9)

Retrieved on: 
Monday, May 3, 2021
Esteve, Battle of Pusan Perimeter, Battles of the Korean War, Battles, Military history of Korea

b'BARCELONA, Spain, May 3, 2021 /PRNewswire/ --Esteve Pharmaceuticals (ESTEVE), an international specialty pharmaceutical company devoted to the development and commercialization of innovative products, today announced an agreement with Kowa Pharmaceuticals America, Inc. (KPA) under which ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States.

Key Points: 
  • b'BARCELONA, Spain, May 3, 2021 /PRNewswire/ --Esteve Pharmaceuticals (ESTEVE), an international specialty pharmaceutical company devoted to the development and commercialization of innovative products, today announced an agreement with Kowa Pharmaceuticals America, Inc. (KPA) under which ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States.
  • A decision on its approval is expected this year.\nESTEVE will be the supplier of the product and will retain worldwide rights to this product, except in the United States and Canada.
  • If approved by FDA, patients and healthcare providers will have access to a new treatment option for acute pain management in adults.
  • "\nBen Stakely, CEO of KPA, said: "We are delighted to be working with an innovative company like ESTEVE to introduce E-58425 to the United States market.

Shick Esteve Promotes Day, Stricker and Nelsen to Organizational Leadership Roles

Retrieved on: 
Monday, April 12, 2021
Shick, Esteve

b'KANSAS CITY, Mo., April 12, 2021 /PRNewswire-PRWeb/ --Shick Esteve, world leader in ingredient automation, today announced the promotion of Blake Day to President, Jason Stricker to VP of Sales & Marketing and Jessica Nelsen to VP Human Resources of Shick Esteve North America, effective immediately.\nDay joined Shick Esteve in 2015 as Chief Financial Officer in Kansas City.

Key Points: 
  • b'KANSAS CITY, Mo., April 12, 2021 /PRNewswire-PRWeb/ --Shick Esteve, world leader in ingredient automation, today announced the promotion of Blake Day to President, Jason Stricker to VP of Sales & Marketing and Jessica Nelsen to VP Human Resources of Shick Esteve North America, effective immediately.\nDay joined Shick Esteve in 2015 as Chief Financial Officer in Kansas City.
  • For the last 13 years he has worked in Regional and Executive Account management for Shick Esteve.
  • He will remain based at Shick Esteve in Kansas City, Missouri.\nNelsen, joined Shick Esteve in 2014 as Human Relations Manager.
  • Since coming to Shick Esteve, Jessica has been instrumental in building the culture, recruiting top talent, and improving the company benefit programs.

Starcity Begins European Expansion With Partnership in Spain

Retrieved on: 
Tuesday, May 19, 2020
Construction & Property, Residential Building & Real Estate, Almirall, Companies, Barcelona, Esteve, Economy of Spain, Spain in the Roman era, Starcity, Barcelona Homes

Starcity is announcing a joint venture today with Barcelona Homes to build housing for the urban renter in Spain.

Key Points: 
  • Starcity is announcing a joint venture today with Barcelona Homes to build housing for the urban renter in Spain.
  • The partnership concludes a year-long effort by Starcity to study the European market.
  • Barcelona was selected as the launch destination for a broader European expansion after careful review.
  • The expansion will be led by Esteve Almirall, Starcitys Managing Director for Spain.